"We want researchers to know what's important
to us."

For more than a decade, Karen Smoot has led an idiopathic pulmonary fibrosis (IPF) support group, helping patients navigate every stage of life with interstitial lung disease. Diagnosed with IPF herself in 2011, she has become a trusted advocate, educator, and Pulmonary Fibrosis Foundation Ambassador.

Attending the inaugural Pulmonary Clinical Trials Workshop (PCT) was more than an opportunity to tell her own story.

"It was an honor to be part of this meeting. I wasn't just representing myself—I was representing people at many different stages of respiratory disease."

As both a patient and a long-time support group leader, Karen sees herself as a bridge between the scientific community and the people living with these diseases every day.

"One of my responsibilities is sharing not only what has already been approved, but also what is happening in clinical trials. People need to know that researchers are working to find better treatments for all forms of interstitial lung disease."

For Karen, patient involvement in scientific meetings is essential because it helps researchers understand what matters beyond clinical data.

"We want the scientific community to know what's important to us."

While finding a cure remains the ultimate goal, she believes patients also want researchers to understand the realities of living with the disease today.

"Quality of life matters. Side effects matter. Patients experience treatments differently, and it's important for researchers and clinicians to hear those perspectives."

She also carries another motivation with her.

"Many of us know there's a familial component to our disease. We're not only doing this for ourselves—we're doing it for the generations that come after us."

One of the sessions that resonated most with Karen focused on lung transplantation and the role that comorbidities play in determining eligibility.

As someone who regularly supports patients facing difficult decisions, she valued hearing directly from experts about how these complex choices are made.

"Many people assume age alone determines whether they're eligible for a transplant. It was valuable to hear the broader discussion and better understand the factors that are really considered."

When asked what she would say to another patient considering attending a meeting like PCT, her answer was immediate.

"It's invaluable."

For many patients, appointments with their pulmonologist are not enough to understand the rapidly evolving research landscape.

"When you're given the opportunity to be in a room with the scientists, physicians, regulators, and researchers focused on your disease, that's an incredible opportunity."

She also encourages patients to explore clinical trials whenever possible and to take advantage of educational resources—even if they cannot attend meetings in person.

"The more informed patients are, the more empowered they become."

Asked to summarize her experience at PCT in one word, Karen chose:

"Fulfilling."

Watching experts from around the world exchange ideas with openness and respect left a lasting impression.

"I loved seeing the discussions between physicians and scientists. They didn't always agree, but they always respected one another's perspectives. That's how progress happens."

For Karen, PCT demonstrated what can be achieved when scientific expertise and lived experience come together. By ensuring patients have a seat at the table, clinical research becomes not only more innovative—but more meaningful.